Clinical Focus ›› 2021, Vol. 36 ›› Issue (5): 432-435.doi: 10.3969/j.issn.1004-583X.2021.05.009
Previous Articles Next Articles
Liu Jiali1, Xie Rong2, Li Xuelian2, Liu Xiaohui1()
Received:
2021-11-22
Online:
2021-05-20
Published:
2021-06-09
Contact:
Liu Xiaohui
E-mail:15328899878@163.com
CLC Number:
Liu Jiali, Xie Rong, Li Xuelian, Liu Xiaohui. Correlation analysis between neutrophil/lymphocyte ratio with Lee’s grading and Oxford classification of IgA nephropathy[J]. Clinical Focus, 2021, 36(5): 432-435.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.05.009
等级 | 病理表现 |
---|---|
Ⅰ级 | 肾小球绝大多数正常,偶尔轻度系膜增宽(节段)伴和(或)不伴细胞增生,肾小管和肾间质没有改变。 |
Ⅱ级 | 肾小球示局灶系膜增殖和硬化(<50%),有罕见小的新月体,肾小管和肾间质无损害。 |
Ⅲ级 | 肾小球呈弥漫性系膜增值和增宽(偶尔局灶节段),偶见小新月体;肾小管和肾间质改变则呈现出局灶性肾间质水肿,偶见细胞浸润,罕见肾小管萎缩。 |
Ⅳ级 | 肾小球病变呈重度弥漫性系膜增生和硬化,部分或全部肾小球硬化,可见新月体(<45%)。肾小管萎缩,肾间质浸润,偶见肾间质泡沫细胞。 |
Ⅴ级 | 肾小球病变的性质类似Ⅳ级,但更严重,肾小球新月体形成>45%;肾小管和肾间质病变类似于Ⅳ级,但更严重。 |
等级 | 病理表现 |
---|---|
Ⅰ级 | 肾小球绝大多数正常,偶尔轻度系膜增宽(节段)伴和(或)不伴细胞增生,肾小管和肾间质没有改变。 |
Ⅱ级 | 肾小球示局灶系膜增殖和硬化(<50%),有罕见小的新月体,肾小管和肾间质无损害。 |
Ⅲ级 | 肾小球呈弥漫性系膜增值和增宽(偶尔局灶节段),偶见小新月体;肾小管和肾间质改变则呈现出局灶性肾间质水肿,偶见细胞浸润,罕见肾小管萎缩。 |
Ⅳ级 | 肾小球病变呈重度弥漫性系膜增生和硬化,部分或全部肾小球硬化,可见新月体(<45%)。肾小管萎缩,肾间质浸润,偶见肾间质泡沫细胞。 |
Ⅴ级 | 肾小球病变的性质类似Ⅳ级,但更严重,肾小球新月体形成>45%;肾小管和肾间质病变类似于Ⅳ级,但更严重。 |
病变部位 | 分级 | 病理表现 |
---|---|---|
系膜增殖(M) | M0 | <4个系膜细胞/系膜区 |
M1 | ≥4个系膜细胞/系膜区 | |
毛细血管内增生性病变(E) | E0 | 无增生性病变 |
E1 | 有增生性病变 | |
节段硬化与粘连(S) | S0 | 无硬化或粘连 |
S1 | 有硬化或粘连 | |
间质纤维化与小管萎缩(T) | T0 | 纤维化或萎缩≤25% |
T1 | 25%<纤维化或萎缩≤50% | |
T2 | 纤维化或萎缩>50% | |
新月体(C) | C0 | 无新月体 |
C1 | 有新月体,且新月体<25% | |
C2 | 有新月体,且新月体≥25% |
病变部位 | 分级 | 病理表现 |
---|---|---|
系膜增殖(M) | M0 | <4个系膜细胞/系膜区 |
M1 | ≥4个系膜细胞/系膜区 | |
毛细血管内增生性病变(E) | E0 | 无增生性病变 |
E1 | 有增生性病变 | |
节段硬化与粘连(S) | S0 | 无硬化或粘连 |
S1 | 有硬化或粘连 | |
间质纤维化与小管萎缩(T) | T0 | 纤维化或萎缩≤25% |
T1 | 25%<纤维化或萎缩≤50% | |
T2 | 纤维化或萎缩>50% | |
新月体(C) | C0 | 无新月体 |
C1 | 有新月体,且新月体<25% | |
C2 | 有新月体,且新月体≥25% |
组别 | 例数 | NLR | hsCRP (mg/L) | SCr (μmol/L) | BUN (mmol/L) | eGFR [ml/(min· 1.73 m2)] | 24 h尿蛋白 (mg) |
---|---|---|---|---|---|---|---|
Ⅰ~Ⅱ级组 | 42 | 2.00(1.62,2.46) | 0.73(0.25,2.02) | 73.20(55.35,93.35) | 4.835(3.880,5.573) | 100.67±32.07 | 800.95(400.88,1 663.35) |
Ⅲ级组 | 14 | 2.57(2.06,3.19) | 0.87(0.23,1.66) | 82.95(68.70,102.00) | 5.255(4.345,5.873) | 85.32±23.39 | 2 435.20(1 105.88,4 796.30) |
Ⅳ~Ⅴ级组 | 18 | 3.20(2.82,4.26) | 1.91(0.33,2.90) | 126.40(95.95,162.65) | 6.540(5.365,9.525) | 57.79±24.94 | 4 215.55(3 218.35,6 428.68) |
统计值 | χ2=22.891 | χ2=1.164 | χ2=17.505 | χ2=9.723 | F=15.187 | χ2=31.25 | |
P值 | <0.05 | >0.05 | <0.05 | <0.05 | <0.05 | <0.05 |
组别 | 例数 | NLR | hsCRP (mg/L) | SCr (μmol/L) | BUN (mmol/L) | eGFR [ml/(min· 1.73 m2)] | 24 h尿蛋白 (mg) |
---|---|---|---|---|---|---|---|
Ⅰ~Ⅱ级组 | 42 | 2.00(1.62,2.46) | 0.73(0.25,2.02) | 73.20(55.35,93.35) | 4.835(3.880,5.573) | 100.67±32.07 | 800.95(400.88,1 663.35) |
Ⅲ级组 | 14 | 2.57(2.06,3.19) | 0.87(0.23,1.66) | 82.95(68.70,102.00) | 5.255(4.345,5.873) | 85.32±23.39 | 2 435.20(1 105.88,4 796.30) |
Ⅳ~Ⅴ级组 | 18 | 3.20(2.82,4.26) | 1.91(0.33,2.90) | 126.40(95.95,162.65) | 6.540(5.365,9.525) | 57.79±24.94 | 4 215.55(3 218.35,6 428.68) |
统计值 | χ2=22.891 | χ2=1.164 | χ2=17.505 | χ2=9.723 | F=15.187 | χ2=31.25 | |
P值 | <0.05 | >0.05 | <0.05 | <0.05 | <0.05 | <0.05 |
组别 | 例数 | NLR | hsCRP (mg/L) | SCr (μmol/L) | BUN (mmol/L) | eGFR [ml/(min· 1.73 m2)] | 24 h尿蛋白 (mg) |
---|---|---|---|---|---|---|---|
T0组 | 49 | 2.05(1.69,2.61) | 0.73(0.24,1.80) | 74.10(58.40,91.40) | 4.75(3.94,5.47) | 94.10(74.63,121.23) | 847.50(450.66,1 730.30) |
T1~T2组 | 25 | 3.01(2.28,4.13) | 1.80(0.31,2.90) | 107.00(89.65,145.90) | 5.99(5.39,8.66) | 65.38(43.46,80.55) | 4 211.50(2 522.60,6 222.25) |
Z值 | -4.309 | -1.136 | -4.524 | -4.739 | -4.138 | -5.750 | |
P值 | <0.05 | >0.05 | <0.05 | <0.05 | <0.05 | <0.05 |
组别 | 例数 | NLR | hsCRP (mg/L) | SCr (μmol/L) | BUN (mmol/L) | eGFR [ml/(min· 1.73 m2)] | 24 h尿蛋白 (mg) |
---|---|---|---|---|---|---|---|
T0组 | 49 | 2.05(1.69,2.61) | 0.73(0.24,1.80) | 74.10(58.40,91.40) | 4.75(3.94,5.47) | 94.10(74.63,121.23) | 847.50(450.66,1 730.30) |
T1~T2组 | 25 | 3.01(2.28,4.13) | 1.80(0.31,2.90) | 107.00(89.65,145.90) | 5.99(5.39,8.66) | 65.38(43.46,80.55) | 4 211.50(2 522.60,6 222.25) |
Z值 | -4.309 | -1.136 | -4.524 | -4.739 | -4.138 | -5.750 | |
P值 | <0.05 | >0.05 | <0.05 | <0.05 | <0.05 | <0.05 |
组别 | 例数 | NLR | hsCRP (mg/L) | SCr (μmol/L) | BUN (mmol/L) | eGFR [ml/(min· 1.73 m2)] | 24 h尿蛋白 (mg) |
---|---|---|---|---|---|---|---|
C0组 | 58 | 2.18(1.75,2.84) | 0.82(0.29,2.09) | 82.50(60.65,111.10) | 5.43(4.56,6.34) | 90.84±34.85 | 1 151.10(616.25,3 190.85) |
C1~C2组 | 16 | 3.00(2.04,3.63) | 1.08(0.24,2.21) | 95.30(73.20,104.00) | 5.29(4.31,6.44) | 74.19±26.54 | 2 837.60(1 453.50,5 673.40) |
统计值 | Z=-2.335 | Z=-0.102 | Z=-1.758 | Z=-0.017 | t=2.205 | Z=-5.750 | |
P值 | <0.05 | >0.05 | <0.05 | >0.05 | <0.05 | <0.05 |
组别 | 例数 | NLR | hsCRP (mg/L) | SCr (μmol/L) | BUN (mmol/L) | eGFR [ml/(min· 1.73 m2)] | 24 h尿蛋白 (mg) |
---|---|---|---|---|---|---|---|
C0组 | 58 | 2.18(1.75,2.84) | 0.82(0.29,2.09) | 82.50(60.65,111.10) | 5.43(4.56,6.34) | 90.84±34.85 | 1 151.10(616.25,3 190.85) |
C1~C2组 | 16 | 3.00(2.04,3.63) | 1.08(0.24,2.21) | 95.30(73.20,104.00) | 5.29(4.31,6.44) | 74.19±26.54 | 2 837.60(1 453.50,5 673.40) |
统计值 | Z=-2.335 | Z=-0.102 | Z=-1.758 | Z=-0.017 | t=2.205 | Z=-5.750 | |
P值 | <0.05 | >0.05 | <0.05 | >0.05 | <0.05 | <0.05 |
指标 | NLR | hsCRP | |||
---|---|---|---|---|---|
r值 | P值 | r值 | P值 | ||
SCr(μmol/L) | 0.507 | 0.000 | 0.145 | 0.198 | |
BUN(mmol/L) | 0.298 | 0.007 | 0.002 | 0.988 | |
eGFR[ml/(min·1.73 m2)] | -0.193 | 0.043 | -0.052 | 0.324 | |
24 h尿蛋白(mg) | 0.527 | 0.000 | 0.035 | 0.761 | |
Lee分级 | 0.578 | 0.000 | 0.106 | 0.347 | |
牛津分型T分级 | 0.485 | 0.000 | 0.128 | 0.259 | |
牛津分型C分级 | 0.263 | 0.019 | 0.011 | 0.920 |
指标 | NLR | hsCRP | |||
---|---|---|---|---|---|
r值 | P值 | r值 | P值 | ||
SCr(μmol/L) | 0.507 | 0.000 | 0.145 | 0.198 | |
BUN(mmol/L) | 0.298 | 0.007 | 0.002 | 0.988 | |
eGFR[ml/(min·1.73 m2)] | -0.193 | 0.043 | -0.052 | 0.324 | |
24 h尿蛋白(mg) | 0.527 | 0.000 | 0.035 | 0.761 | |
Lee分级 | 0.578 | 0.000 | 0.106 | 0.347 | |
牛津分型T分级 | 0.485 | 0.000 | 0.128 | 0.259 | |
牛津分型C分级 | 0.263 | 0.019 | 0.011 | 0.920 |
[1] |
Béné MC, Hurault De Ligny B, Kessler M, et al. Confirmation of tonsillar anomalies in IgA nephropathy: A multicenter study[J]. Nephron, 1991, 58(4):425-428.
pmid: 1922607 |
[2] | Yang Y, Zhang Z, Zhuo L, et al. The spectrum of biopsy-proven glomerular disease in China: A systematic review[J]. Chin Med J (Engl), 2018, 131(6):731-735. |
[3] | Paquissi FC. The role of inflammation in cardiovascular diseases: The predictive value of neutrophil-lymphocyte ratio as a marker in peripheral arterial disease[J]. Ther Clin Risk Manag, 2016, 12:851-860. |
[4] |
Pine JK, Morris E, Hutchins GG, et al. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: The relationship to patient survival, tumour biology and local lymphocytic response to tumour[J]. Br J Cancer, 2015, 113(2):204-211.
doi: 10.1038/bjc.2015.87 URL |
[5] | 张国娟, 黄雯, 陈燊. 中性粒细胞淋巴细胞比值在评价慢性肾脏病患者炎症状态中的作用[J]. 中国血液净化, 2015, 14(4):482-485. |
[6] | 邹万忠. 肾活检病理学[M].第2版. 北京大学医学出版社, 2009:58-169. |
[7] |
Zhou FD, Zhao MH, Zou WZ, et al. The changing spectrum of primary glomerular diseases within 15 years: A survey of 3331 patients in a single Chinese centre[J]. Nephrol Dial Transplant, 2009, 24(3):870-876.
doi: 10.1093/ndt/gfn554 URL |
[8] |
Feriozzi S, Polci R. The role of tonsillectomy in IgA nephropathy[J]. J Nephrol, 2016, 29(1):13-19.
doi: 10.1007/s40620-015-0247-4 pmid: 26582216 |
[9] |
Zhu TT, Wang L, Wang HL, et al. Helicobacter pylori participates in the pathogenesis of IgA nephropathy[J]. Ren Fail, 2016, 38(9):1398-1404.
doi: 10.1080/0886022X.2016.1216713 URL |
[10] |
Rollino C, Vischini G, Coppo R. IgA nephropathy and infections[J]. J Nephrol, 2016, 29(4):463-468.
doi: 10.1007/s40620-016-0265-x URL |
[11] | Guo ZX, Wei W, Zhong C, et al. Correlation of preoperative neutrophil-to-lymphocyte ratio to prognosis of young patients with hepatocellular carcinoma[J]. Ai Zheng, 2009, 28(11):1203-1208. |
[12] |
Hu ZD, Sun Y, Guo J, et al. Red blood cell distribution width and neutrophil/lymphocyte ratio are positively correlated with disease activity in primary Sjögren's syndrome[J]. Clin Biochem, 2014, 47(18):287-290.
doi: 10.1016/j.clinbiochem.2014.08.022 URL |
[13] |
Uslu AU, Küçük A, Şahin A, et al. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio[J]. Int J Rheum Dis, 2015, 18(7):731-735.
doi: 10.1111/apl.2015.18.issue-7 URL |
[14] | 赵春梅, 袁宏伟. IgA肾病组织病理学特点与临床预后关系研究[J]. 中华实用诊断与治疗杂志, 2015, (6):589-590. |
[15] | 李卅立, 范秋灵, 赵洁, 等. IgA肾病牛津分型与临床指标的相关性及危险因素分析[J]. 中国医科大学学报, 2017, 46(1):1-6. |
[16] |
Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: Clinical and histological response to methylprednisolone and intravenous cyclophosphamide[J]. Nephrol Dial Transplant, 2003, 18(7):1321-1329.
doi: 10.1093/ndt/gfg081 URL |
[17] | 杨艳燕, 陶涛, 罗朋立, 等. 不同中性粒细胞与淋巴细胞比值IgA肾病患者临床特征比较及其影响因素分析[J]. 山东医药, 2018, 58(46):49-52. |
[18] | 张春雷, 李欣蓉, 曾学辉. 炎症介质在IgA肾病中的临床应用价值探讨[J]. 免疫学杂志, 2018, 34(4):348-352. |
[19] |
Huang W, Huang J, Liu Q, et al. Neutrophil-lymphocyte ratio is a reliable predictive marker for early-stage diabetic nephropathy[J]. Clin Endocrinol (Oxf), 2015, 82(2):229-233.
doi: 10.1111/cen.12576 URL |
[1] | Wang Tao, Gao Yuwei, Wang Xinghua, Hu Xiuhong, Cui Hongrui, Xu Baozhen, Yang Hongjuan. Correlation of anti-phospholipase A2 receptor antibody with idiopathic membranous nephropathy [J]. Clinical Focus, 2023, 38(7): 606-612. |
[2] | Gao Qinyu, Bao Beiyan, Jin Yan, Zhao Yu. Analysis of clinical features and prognostic factors of IgA nephropathy complicated with depression [J]. Clinical Focus, 2023, 38(6): 510-515. |
[3] | Gao Pengli, Chen Lili, Tian Fen, Zhang Jiaqian, Chen Yipeng, Qi Xiaojing, Xing Guangqun. Impact of body mass index in the clinicopathology and prognosis of patients with IgA nephropathy [J]. Clinical Focus, 2022, 37(3): 234-242. |
[4] | Di Dingxin, Zhang Zheng, Li Yetong, Zou Guming, Gao Hongmei, Li Wenge. Treatment and prognosis of malignant hypertension complicated with thrombotic microangiopathy for young IgAN patients [J]. Clinical Focus, 2021, 36(3): 256-261. |
[5] | Huo Xiaoxia, Niu Weiwei, Han Xu, Zhang Xiaolan. Effects of dense ligation on liver function and hemodynamics in patients with esophageal variceal bleeding [J]. Clinical Focus, 2021, 36(3): 238-241. |
[6] | Song Junzhen, Shi Cuiying, Wang Fenghong, Ma Yuanyuan, Zhao Qian. Investigation on current situation of clinical blood management in tertiary general hospitals of Hebei province [J]. Clinical Focus, 2021, 36(2): 157-161. |
[7] | Li Yi, Ji Gaorong. Clinical value of serum YKL40, CCL18 and hscTnT in predicting adverse cardiovascular events in patients with acute myocardial infarction [J]. Clinical Focus, 2020, 35(3): 211-215. |
[8] | Fu Shuxia1, Fu Shuli2. Advances in the treatment of idiopathic membranous nephropathy [J]. Clinical Focus, 2019, 34(12): 1061-1065. |
[9] | Dong Hu, Zhang Beiru, Li Luting, He Ping, Wang Yanqiu, Sun Guangping. Changes in pathological spectrum of primary glomerulonephritis——a single center data [J]. Clinical Focus, 2018, 33(7): 595-598,602. |
[10] | Liu Likun, Liang Juyou, Chen Jing, Yao Yao, Guo Meng, Li Xiaona, Zhao Junli, Zhao Yiran, Xing Qiaoling, Pan Hongjuan, Li Xutong. Study on the identification of a case with blood type B(A) and the concerned clinical safety transfusion strategies [J]. Clinical Focus, 2018, 33(6): 510-514. |
[11] | Yin Kaige, Jin Xiaoxu, Feng Zhijie. Endoscopic treatment of esophagogastric varices in cirrhosis [J]. Clinical Focus, 2018, 33(11): 929-932. |
[12] | Zhang Wenxian, Tian Menglei, Zhao Song, Chi Yanqing, Liu Maodong, Li Ying. The clinical significance of serum antibodies of PLA2R and THSD7A in idiopathic membranous nephropathy [J]. Clinical Focus, 2018, 33(10): 873-877,882. |
[13] | Lu Yue, Li Shaomei. Role of M-type phospholipase A2 receptor and its antibody in diagnosis and treatment of idiopathic membranous nephropathy [J]. Clinical Focus, 2018, 33(10): 839-845. |
[14] | Wang Yuhui1, Guan Xin2, Zheng Hongguang2, Wang Shaxi2, Chen Jianhua1. Study on clinicopathological and treatment of IgM nephropathy [J]. Clinical Focus, 2017, 32(7): 571-574. |
[15] | Shen Mengjiao1, Dai Xiahua2, Wang Jiapei1, Zheng Jika2, Di Yazhen2,Zhong Shiling2, Ying Qianqian1, Fu Shiwei1. Urine monocyte chemoattractant protein1 in HenochSchonlein purpura children with nephritis [J]. Clinical Focus, 2017, 32(5): 409-412. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||